Cost-effectiveness of diabetes medications
Pro Research Analysisby 
Searched over 200M research papers
Cost-Effectiveness of Newer Diabetes Medications: SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors
Recent systematic reviews consistently show that newer antidiabetic drugs—specifically sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and dipeptidyl peptidase-4 inhibitors (DPP-4i)—are generally more cost-effective than older medications like insulin, sulfonylureas, and thiazolidinediones, especially when used as second-line therapy after metformin in type 2 diabetes 23. SGLT2 inhibitors, in particular, are often found to be more cost-effective than GLP-1 receptor agonists and DPP-4 inhibitors in patients not adequately controlled by metformin alone 24. However, the cost of these newer drugs is a major factor influencing their overall value, and results can vary depending on local drug prices and healthcare system perspectives 234.
First-Line Versus Add-On Therapy: Value Assessment
When used as first-line therapy, GLP-1 receptor agonists and SGLT2 inhibitors are considered low value compared to metformin due to their high costs and only modest additional health benefits . However, when these drugs are added to metformin or other background therapy, their cost-effectiveness improves and may reach intermediate value, though this is still sensitive to drug pricing and effectiveness assumptions . DPP-4 inhibitors are sometimes more cost-effective than traditional drugs, but SGLT2 inhibitors and sulfonylureas often provide better economic value as second-line options 23.
Insulin Analogs and Biosimilars: Cost-Effectiveness in Type 2 Diabetes
Insulin analogues, including long-acting and ultralong-acting formulations, are generally cost-effective for type 1 diabetes, but evidence for their cost-effectiveness in type 2 diabetes is less convincing . Long-acting insulins may be more cost-effective than intermediate-acting insulins, and ultralong-acting insulins are often cost-effective compared to other long-acting options . However, insulin analogues are typically more expensive than older insulins like NPH, and their value depends on reductions in hypoglycemia and improved glycemic control 169.
Impact of Rising Drug Costs on Cost-Effectiveness
The increasing price gap between newer and older glucose-lowering drugs has reduced the cost-effectiveness of newer agents over time. When updated to reflect recent drug prices, many cost-effectiveness analyses now favor older drugs such as sulfonylureas and thiazolidinediones over newer agents, except when compared to insulin, where newer drugs may still be cost-effective . This highlights the importance of considering current drug prices and potential rebates when evaluating economic value 17.
Methodological Considerations and Limitations
Most cost-effectiveness studies use validated diabetes models and are of good reporting quality, but many are industry-sponsored, which may introduce bias 34. There are also limitations in model assumptions, such as outdated risk equations and insufficient consideration of patient subgroups, which can affect the reliability of results . Additionally, the value of newer drugs is highly sensitive to assumptions about their effectiveness and cost 14.
Medication Adherence and Lifestyle Interventions
Improving medication adherence is more cost-effective than lifestyle interventions like diet and exercise from a payer perspective, though both approaches can reduce complications and improve quality-adjusted life years (QALYs) . Long-term adherence interventions yield the greatest health and economic benefits, but require investment in trained personnel .
Global Access and Affordability Challenges
High costs of newer diabetes medications limit their availability in developing countries, where pharmaceutical pricing does not always reflect local economic conditions. This creates significant barriers to access and places pressure on healthcare budgets, especially in low-income settings .
Conclusion
Newer antidiabetic medications, particularly SGLT2 inhibitors, are often cost-effective as second-line therapy for type 2 diabetes, but their value is highly dependent on drug costs and local healthcare system factors. As drug prices rise, the cost-effectiveness of these agents compared to older drugs diminishes. Insulin analogues are generally cost-effective for type 1 diabetes, but evidence is less clear for type 2 diabetes. Improving medication adherence remains a highly cost-effective strategy. Policymakers should consider both clinical benefits and economic realities when making decisions about diabetes medication coverage and reimbursement.
Sources and full results
Most relevant research papers on this topic
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
Newer antidiabetic drugs, especially SGLT2i, are cost-effective as second-line treatments for type 2 diabetes, with GLP-1RA being the most cost-effective option.
Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus
Insulin analogues are cost-effective for treating type 1 diabetes mellitus, but their use in type 2 diabetes mellitus is not convincing.
810-P: The Diminishing Cost-Effectiveness of the Newer Glucose-Lowering Drugs in the United States, 2010-2018
Newer glucose-lowering drugs are less cost-effective than older drugs, with 58% of studies favoring older drugs after cost updates.
Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis
Strategy 7 is the most cost-effective strategy for type 2 diabetes treatment, providing higher QALYs but lower costs compared to other strategies.
The Cost-Effectiveness Of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
Long-acting insulin may be cost-effective compared to intermediate-acting insulin for type 1 diabetes patients, with ultralong-acting insulin being the most cost-effective option.
DOI